According to Fintel’s report on September 15, 2023, Cantor Fitzgerald reiterated its coverage of Ascendis Pharma A (NASDAQ:ASND) with an Overweight recommendation.
Analyst Price Forecast suggests a 36.40% upside
As of August 31, 2023, the average one-year price target for Ascendis Pharma A is $141.02. The forecasts range from a low of $89.89 to a high of $196.35. The average price target represents an increase of 36.40% from its latest reported closing price of $103.39.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ascendis Pharma A is $152MM, an increase of 27.93%. The projected annual non-GAAP EPS is -$9.74.
What is the Fund Sentiment?
There are 405 funds or institutions reporting positions in Ascendis Pharma A. This is a decrease of 10 owners or 2.41% in the last quarter. The average portfolio weight of all funds dedicated to ASND is 0.47%, a decrease of 21.84%. Total shares owned by institutions increased in the last three months by 2.20% to 78,494K shares. 
The put/call ratio of ASND is 1.42, indicating a bearish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 11,225K shares representing 19.97% ownership of the company. In its prior filing, the firm reported owning 6,957K shares, representing an increase of 38.02%. The firm increased its portfolio allocation in ASND by 12.02% over the last quarter.
Artisan Partners Limited Partnership holds 6,222K shares representing 11.07% ownership of the company. In its prior filing, the firm reported owning 6,845K shares, representing a decrease of 10.00%. The firm decreased its portfolio allocation in ASND by 26.01% over the last quarter.
T. Rowe Price Investment Management holds 3,983K shares representing 7.08% ownership of the company. In its prior filing, the firm reported owning 3,473K shares, representing an increase of 12.79%. The firm decreased its portfolio allocation in ASND by 9.32% over the last quarter.
Janus Henderson Group holds 3,881K shares representing 6.90% ownership of the company. In its prior filing, the firm reported owning 3,533K shares, representing an increase of 8.98%. The firm decreased its portfolio allocation in ASND by 14.83% over the last quarter.
Westfield Capital Management Co holds 3,632K shares representing 6.46% ownership of the company. In its prior filing, the firm reported owning 3,146K shares, representing an increase of 13.37%. The firm decreased its portfolio allocation in ASND by 13.61% over the last quarter.
Ascendis Pharma A Background Information(This description is provided by the company.)
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science, and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
